(Q33878228)

29 July 2017

1 reference

title

Clinical evidence with montelukast in the management of chronic childhood asthma (English)

1 reference

29 July 2017

1 reference

Becker A

1

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

59 Suppl 1

1 reference

29 July 2017

29-34; discussion 43-5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200059001-00005

29 July 2017

0 references

cites work

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059001-00005

Urinary leukotriene E after exercise challenge in children with asthma

21 January 2018

1 reference

12 December 2020

Exercise-induced asthma: update on pathophysiology, clinical diagnosis, and treatment

1 reference

12 December 2020

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

12 December 2020

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

12 December 2020

The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

1 reference

12 December 2020

Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist

1 reference

12 December 2020

The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock

1 reference

12 December 2020

Effects of leukotriene D on the airways in asthma

1 reference

12 December 2020

Leukotriene D4 induces MMP-1, which functions as an IGFBP protease in human airway smooth muscle cells

1 reference

12 December 2020

The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin

1 reference

12 December 2020

Measuring quality of life in children with asthma.

1 reference

12 December 2020

Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate

1 reference

12 December 2020

Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro

1 reference

12 December 2020

Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children

1 reference

12 December 2020

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

12 December 2020

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics

1 reference

12 December 2020

Persistent increase in plasma and urinary leukotrienes after acute asthma

1 reference

12 December 2020

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

12 December 2020

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

12 December 2020

The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo

1 reference

12 December 2020

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

12 December 2020

Is there a unifying hypothesis for exercise-induced asthma?

1 reference

12 December 2020

Exercise-induced airway obstruction.

1 reference

12 December 2020

Urinary leukotriene E4 levels during early and late asthmatic responses†

1 reference

12 December 2020

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

12 December 2020

Prevention of exercise induced asthma by inhaled salmeterol xinafoate

1 reference

12 December 2020

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

1 reference

12 December 2020

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma

1 reference

12 December 2020

Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis

1 reference

12 December 2020

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

1 reference

12 December 2020

Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma

1 reference

12 December 2020

10.2165/00003495-200059001-00005

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference

PubMed ID

10741880